Journal highlights dupilumab efficacy study in Chinese patients with persistent type 2 asthma
Clinical & Experimental Allergy shared a new article on dupilumab in patients from China with persistent type 2 asthma, with and without an allergic phenotype.
“Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype”— Clinical & Experimental Allergy
Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology, highlighted a research article on dupilumab in asthma in a post on X on 10 November 2026.
The article is titled "Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype". Going by the title, it examines how effective dupilumab is in patients from China who have persistent type 2 asthma, including those with and without an allergic phenotype.
The post does not give any results, study design, patient numbers or author names. It carried the hashtags #Asthma, #AllergicAsthma and #Dupilumab, tagged the accounts @BSACI_Allergy, @EAACI_HQ and @APAAACI1, and included a link to the article.
Readers seeking the findings will need to consult the full paper through the link in the journal's post.
Original source
“Efficacy of Dupilumab in Patients From China With Persistent Type 2 Asthma With and Without an Allergic Phenotype”
— Clinical & Experimental Allergy View the post on X
